Aclaris Therapeutics, Inc.
ACRS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACRS
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small and large molecule therapies for difficult-to-drug kinase targets, with lead programs in dermatology and immunology.
Key risk: Clinical development delays
BioSniper Score
Based on 6 of 6 signals
Market Cap
$884.7M
Cash Runway
13.6 moLead Asset
ATI-2138 (Phase 2)
Next Catalyst
Patent_Expiry · Jul 4, 2035Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 1 catalyst for Aclaris Therapeutics, Inc..
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small and large molecule therapies for difficult-to-drug kinase targets, with lead programs in dermatology and immunology.
- Aclaris is a clinical-stage biopharmaceutical company focused on developing novel small and large molecule therapies [sec_mda · as of 2026-08-06].
- The company's approach includes reversible/irreversible covalent inhibitors, molecular glue/complex targeted inhibitors, and targeted protein degraders for difficult-to-drug kinase targets [sec_mda · as of 2025-08-07].
- As of 2026-06-30, Aclaris reported cash & equivalents of $19.2M, total revenue of $1.6M, and a net loss of -$21.5M [sec].
- As of December 31, 2025, the company had an accumulated deficit of $967.8 million [sec_mda · as of 2026-02-26].
- Aclaris expects to initiate a Phase 2b trial of ATI-052 in atopic dermatitis (AD) in the second half of 2026 [sec · filed 2026-01-06].
What works
- Aclaris has a differentiated platform targeting difficult-to-drug kinases using multiple novel modalities (covalent inhibitors, molecular glues, protein degraders) [sec_mda · as of 2025-08-07].
- The company has ongoing clinical programs with top-line data from two trials expected in the second half of 2026, providing potential catalysts [sec · filed 2026-01-06].
What to weigh
- Aclaris has a significant accumulated deficit of $967.8 million as of December 31, 2025, and expects to continue incurring operating losses [sec_mda · as of 2026-02-26].
- The company's cash position of $19.2M as of 2026-06-30 is limited relative to its net loss rate, raising potential near-term funding needs [sec].
- Aclaris faces uncertainty in clinical development timelines, including patient enrollment, trial costs, and regulatory approval risks [sec_mda · as of 2026-02-26].
From the filings
Quoted directly from source documents.
Aclaris is a clinical-stage biopharmaceutical company focused on developing novel small and large molecule therapies.
“We are a clinical-stage biopharmaceutical company focused on developing novel small and lar”
SEC MD&A · August 6, 2026
The company uses novel inhibitor modalities including covalent inhibitors, molecular glues, and targeted protein degraders.
“Our approach involves the following mechanisms: (1) reversible and irreversible covalent inhibitors, (2) molecular glue/complex targeted inhibitors and (3) targeted protein degraders.”
SEC MD&A · August 7, 2025
Aclaris expects to initiate a Phase 2b trial of ATI-052 in AD in the second half of 2026.
“The Company is also planning for a Phase 2b trial of ATI-052 in AD, which the Company expects to initiate in the second half of 2026.”
SEC filings · January 6, 2026
As of December 31, 2025, accumulated deficit was $967.8 million.
“As of December 31, 2025, we had an accumulated deficit of $967.8 million.”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2035-07-04 · Patent_Expiry · ESKATA — Patent/Exclusivity Expiry: ESKATA — Patent/exclusivity expiry for ESKATA, which may affect market exclusivity for that product.
Risks & what to watch (3)›
Key risks
- Clinical development delays — Uncertainty in patient enrollment, trial costs, and regulatory approval timelines could delay programs [sec_mda · as of 2026-02-26].
- Limited cash runway — Cash of $19.2M as of 2026-06-30 may not sustain operations without additional financing given ongoing net losses [sec].
- Regulatory approval risk — Failure to obtain FDA approval for product candidates would prevent commercialization [sec_mda · as of 2026-05-07].
What to watch
- Top-line data from two clinical trials expected in the second half of 2026 [sec · filed 2026-01-06].
- Initiation of Phase 2b trial for ATI-052 in atopic dermatitis in the second half of 2026 [sec · filed 2026-01-06].
- Cash position updates and potential financing activities given limited runway [sec].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Aclaris Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aclaris Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
13.6 months
D/E 0.44 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~3230d
0 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
133
Total value held
$322.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 10,334,938 | $38.8M |
| deep track capital, lp | 9,345,000 | $35.0M |
| blackrock, inc. | 7,407,065 | $27.8M |
| ra capital management, l.p. | 6,804,072 | $25.5M |
| rock springs capital management lp | 4,472,650 | $16.8M |
| adage capital partners gp, l.l.c. | 3,871,000 | $14.5M |
| balyasny asset management l.p. | 3,361,328 | $12.6M |
| kalehua capital management llc | 3,169,921 | $11.9M |
| woodline partners lp | 2,971,246 | $11.1M |
| citadel advisors llc | 2,818,019 | $10.6M |
Showing top 10 of 133 institutional holders of Aclaris Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.5%
- Days to cover
- 5.5
- Shares short
- 7,889,202
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACRS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aclaris Therapeutics, Inc.?
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small and large molecule therapies for difficult-to-drug kinase targets, with lead programs in dermatology and immunology.
What is Aclaris Therapeutics, Inc.'s lead drug candidate?
Aclaris Therapeutics, Inc.'s most advanced tracked candidate is ATI-2138 (Phase 2) for Atopic Dermatitis.
What is Aclaris Therapeutics, Inc.'s next catalyst?
Aclaris Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ESKATA" — expected July 4, 2035.
Who is the CEO of Aclaris Therapeutics, Inc.?
Dr. Neal S. Walker D.O., M.D. is the chief executive officer of Aclaris Therapeutics, Inc. (ACRS).
Where is Aclaris Therapeutics, Inc. headquartered?
Aclaris Therapeutics, Inc. (ACRS) is headquartered in Wayne, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.